GT Biopharma (Nasdaq:GTBP) - Aandelenkoers, Nieuws & Analyse

GTBP Overzicht aandelen

GTBP fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $7M )

Heeft minder dan 1 jaar cash runway

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

+ 1 meer risico

GT Biopharma, Inc. Concurrenten

Edesa Biotech

NasdaqCM:EDSA

US$7.0m

TransCode Therapeutics

NasdaqCM:RNAZ

US$6.6m

ABVC BioPharma

NasdaqCM:ABVC

US$6.6m

Aptinyx

OTCPK:APTX

US$6.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor GT Biopharma
Historische aandelenkoersen
Huidige aandelenkoers	US$3.06
52 Week Hoogtepunt	US$10.66
52 Week Laag	US$1.92
Bèta	0.57
11 maand verandering	-1.92%
3 maanden verandering	41.67%
1 Jaar Verandering	-57.87%
33 jaar verandering	-97.70%
5 jaar verandering	-95.38%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	GTBP	US Biotechs	US Markt
7D	4.8%	2.5%	2.2%
1Y	-57.9%	16.1%	31.6%

Rendement versus industrie: GTBP presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.1 % opleverde.

Rendement versus markt: GTBP presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is GTBP's price volatile compared to industry and market?
GTBP volatility
GTBP Average Weekly Movement	10.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van GTBP is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van GTBP is het afgelopen jaar gedaald van 24% naar 11%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1965	2	Michael Breen	www.gtbiopharma.com

GT Biopharma, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van immuno-oncologische producten gebaseerd op zijn eigen Tri-specific Killer Engager (TriKE) fusie-eiwit immuuncel engager technologieplatform. Het ontwikkelt GTB-3550, een enkel-keten tri-specifiek recombinant fusie-eiwitconjugaat dat zich in Fase I van de klinische studie bevindt voor de behandeling van myelodysplastische syndromen, refractaire/relapsed acute myeloïde leukemie of gevorderde systemische mastocytose, en CD33+ maligniteiten. Het bedrijf ontwikkelt GTB-3650, dat zich in preklinische studies bevindt en gericht is tegen CD33 op het oppervlak van myeloïde leukemieën; en GTB-5550 dat zich in preklinische studies bevindt voor de behandeling van patiënten met B7-H3-positieve solide tumoren.

GT Biopharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van GT Biopharma zich tot de beurswaarde?
GTBP fundamentele statistieken
Marktkapitalisatie	US$6.84m
Inkomsten(TTM)	-US$12.35m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.6x

Koers/Winstverhouding

Is GTBP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GTBP resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$12.35m
Inkomsten	-US$12.35m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-5.53
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde GTBP op de lange termijn?

Bekijk historische prestaties en vergelijking

GTBP Overzicht aandelen

Risicoanalyse

GT Biopharma, Inc. Concurrenten

NasdaqCM:EDSA

US$7.0m

NasdaqCM:RNAZ

US$6.6m

NasdaqCM:ABVC

US$6.6m

OTCPK:APTX

US$6.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces CFO Changes

New major risk - Shareholder dilution

GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million.

New major risk - Financial position

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

Recent updates

GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces CFO Changes

New major risk - Shareholder dilution

GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million.

New major risk - Financial position

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Share price stability

GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance

New major risk - Revenue and earnings growth

New major risk - Market cap size

GT Biopharma, Inc. Announces Board Changes

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

Price target decreased to US$4.00

High number of new and inexperienced directors

GT Biopharma files for $150M mixed shelf offering

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index

GT Biopharma, Inc. Appoints Alan L. Urban to Fill Vacant Seat on Board

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

GT Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$17.33

High number of new and inexperienced directors

GT Biopharma, Inc. Announces CEO Changes

GT Biopharma, Inc Appoints Manu Ohri as Chief Financial Officer

Price target decreased to US$17.33

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Price target increased to US$25.33

High number of new and inexperienced directors

GT Biopharma Announces Updated Positive Safety Data from Phase 1 GTB-3550 Monotherapy Trike Trial an Investigational Immunotherapy for Refractory Cancers to Be Presented At ESMO Congress 2021

GT Biopharma, Inc. Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

GT Biopharma, Inc. announced delayed 10-Q filing

GT Biopharma Provides Second Quarter 2021 Business Update

Price target increased to US$25.33

GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results

Getting To Know GT Biopharma

GT Biopharma, Inc. Announces Update on the Commencement of the GTB-3550 Trike Monotherapy Phase 2 Clinical Trial and Solid Tumor Trike Product Candidates

GT Biopharma names Gregory Berk Chief Medical Officer

GT Biopharma, Inc. announced delayed annual 10-K filing

GT Biopharma, Inc. Updates Interim GTB-3550 Trike™ Clinical Trial Results

GT Biopharma, Inc. Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

GT Biopharma, Inc. Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment

Gt Biopharma, Inc. Sign an Expanded GMP Manufacturing Agreement with Cytovance Biologics

GT Biopharma, Inc. has completed a Composite Units Offering in the amount of $23.65 million.

GT Biopharma, Inc. Announces Board Changes

GT Biopharma Announces Eighth Patient Begins Treatment of GTB-3550

GT Biopharma, Inc. Announces TriKE™ for the Treatment of Breast and GI Cancers

Gt Biopharma, Inc. and Cytovance Reaches Agreement for License Rights to Use Certain Bacterial and Mammalian Cell Lines and for GMP Manufacturing Services Performed to Date Regarding the Company's Trike™ Product Candidates

Dr. Greg Berk, M.D. Joins Board of Directors of GT Biopharma, Inc

GT Biopharma, Inc. Appoints Michael Handelman as Chief Financial Officer

GT Biopharma, Inc. Announces Advisory Board Appointments

GT Biopharma, Inc. announced that it has received $0.25 million in funding

GT Biopharma, Inc. announced that it has received $5.607 million in funding